On July 27, 2016, the Federal Trade Commission (“FTC”) cleared to generic pharmaceutical deals. Mylan/Meda Deal Mylan, N.V. agreed to divest the rights and assets related to two generic products to settle allegations that its proposed $7.2 billion acquisition of Meda AB would be anticompetitive. Under the terms of the…
Updated: